Patient Access to Radiopharmaceuticals, Part 2

In the second part of PharmTech’s interview with Nicholas Richardson, vice president of clinical development at Precision for Medicine, Richardson explains how effective patient access planning in radiopharmaceutical development hinges on a well-defined site strategy and an integrated supply chain. Identifying centers of excellence with established nuclear medicine capabilities is essential, according to Richardson, as these sites offer the infrastructure and readiness required to support clinical trials. Equally important is the selection of paired isotopes that enable scalability, ensuring product availability for just-in-time delivery as development programs expand.

A differentiator in radiopharmaceutical development is the theranostic model, which is the co-development of diagnostic and therapeutic agents. This approach is patient-centric, allowing real-time biodistribution imaging specific to the individual, which in turn enables personalized therapeutic dosing. For manufacturers, this represents both a scientific and logistical opportunity to align production capabilities with precision medicine demands.

Patient burden is another consideration that affects trial enrollment and retention. Radiopharmaceutical schedules of assessment are often shaped by isotope half-life and development stage, frequently necessitating inpatient hospitalization. Development teams should actively seek opportunities to incorporate outpatient components where feasible, reducing time demands on patients while maintaining protocol integrity, according to Richardson. Minimizing the frequency of required assessments, where scientifically permissible, can further ease patient burden and support successful trial conduct.

Radiopharmaceuticals require an integrated therapeutic system to ensure safe administration and reliable access for oncology patients. The field has seen an increase in development activity, with several products reaching approval. As the industry scales to meet this demand, a coordinated, systematic approach across manufacturing, logistics, and clinical operations will be essential to delivering these targeted therapies to patients with serious and life-threatening cancers.

About the Speaker

Nicholas Richardson is a hematologist oncologist and vice president of clinical development at Precision for Medicine, an oncology and rare disease-focused contract research organization. Prior to joining Precision, Richardson was formerly at the FDA for nearly 10 years as a prior FDA oncology, deputy director.